User:Mr. Ibrahem/Daratumumab

Daratumumab, sold under the brand name Darzalex, is a medication used to treat multiple myeloma (MM) and light chain amyloidosis. In MM it is used when other treatments have failed. It is given by injection into a vein or under the skin.

Common side effects include infusion reactions, tiredness, fever, nausea, diarrhea, swelling, cough, shortness of breath, peripheral neuropathy, and low blood cells. Other side effects may include pneumonia, pulmonary edema, sepsis, and atrial fibrillation. Use in pregnancy may harm the baby. It is a monoclonal antibody which binds to CD38, and activates the immune system to kill the cells in question.

Daratumumab was approved for medical use in the United States in 2015 and Europe in 2017. In the United Kingdom 1,800 mg cost the NHS about £4,300 as of 2021. This amount in the United States costs about 11,000 USD.